Year archive

Sandoz Group AG — 2026 filings

All 26 regulatory filings released by Sandoz Group AG (SDZ) in 2026, sourced directly from the official regulator.

26 Filings

2026 Period

2026 filings (26)

Filing	Released	Lang
Sandoz confirms European Commission approval for biosimilars Bysumlog (insulin lispro) and Dazparda (insulin aspart), strengthening position in diabetes Regulatory Filings	2026-05-15	English
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes Regulatory Filings	2026-05-15	English
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed Earnings Release Q1 2026	2026-04-29	English
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed Earnings Release Q1 2026	2026-04-29	English
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets Regulatory Filings	2026-04-15	English
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets Regulatory Filings	2026-04-15	English
Twenty years of biosimilar medicines: a milestone that continues to transform patient access worldwide Regulatory Filings	2026-04-13	English
Twenty years of biosimilar medicines: a milestone that continues to transform patient access worldwide Regulatory Filings	2026-04-13	English
Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG Declaration of Voting Results & Voting Rights Announcements	2026-04-09	English
Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG Declaration of Voting Results & Voting Rights Announcements	2026-04-09	English
Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets Regulatory Filings	2026-03-18	English
Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets Regulatory Filings	2026-03-18	English
Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year Capital/Financing Update	2026-03-11	English
Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year Capital/Financing Update	2026-03-11	English
Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth Board/Management Information	2026-03-10	English
Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth Board/Management Information	2026-03-10	English
Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth Report Publication Announcement	2026-02-25	English
Sandoz confirms European Commission approval for Ranluspec (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology Regulatory Filings	2026-02-23	English
Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology Regulatory Filings	2026-02-23	English
Sandoz receives US FDA approval to expand Enzeevu (aflibercept-abzv) label for multiple retinal indications Regulatory Filings	2026-02-18	English
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications Regulatory Filings	2026-02-18	English
Test 2 Headline 30.01.26 Regulatory Filings	2026-01-30	English
Sandoz confirms European Commission approval of Ondibta (insulin glargine), strengthening overall biosimilars leadership and position in diabetes Regulatory Filings	2026-01-14	English
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes Regulatory Filings	2026-01-14	English
Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented golden decade of affordable medicines opportunity Earnings Release FY 2024	2026-01-12	English
Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity Regulatory Filings	2026-01-12	English